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Abstract
Background: High early morbidity and mortality following antiretroviral therapy (ART) initiation has been a
distinguishing feature of ART programmes in resource limited settings (RLS) compared to high-income countries.
This study assessed how well body mass index (BMI: kg/m2) correlated with survival among HIV infected patients
with and without TB co-infection.
Methods: We retrospectively evaluated clinical data from 1000 HIV infected patients, among whom 389 were also
co-infected with TB, between January 2008 and December 2010, in KwaZulu-Natal, South Africa.
Results: Among 948 patients eligible for analysis, 15.7% (149/948) were underweight (< 18.50), 55.9% (530/948) had
normal BMI (≥18.50–24.90), 18.7% (177/948) were overweight (25.00–29.00) and 9.7% (92/948) were obese (≥30.00).
Irrespective of TB status, underweight patients, had significantly higher risk of death compared to those with normal
BMI at baseline (aHR = 2.9; 95% CI: 1.5–5.7; P = 0.002).
Conclusions: Irrespective of TB co-infection, low BMI correlated with mortality in HIV infected patients.
Trial registration: UKZN Biomedical Research Ethics Committee Reference number E 248/05, 23 September 2005.
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Multilingual abstracts
Please see Additional file 1 for translations of the ab-
stract into the five official working languages of the
United Nations.
Background
Human immunodeficiency virus (HIV) infection creates
serious health and developmental challenges, especially
in resource limited settings [1]. Since first reported, ap-
proximately 36 million people have died from disease
associated with acquired immune deficiency syndrome
(AIDS), and another 35.3 million are currently living
with HIV/AIDS, worldwide [1]. While the introduction
and scale-up of ART has reduced overall mortality, high
early morbidity and mortality following ART initiation,
remains a distinguishing feature of ART programs in
sub-Saharan Africa [2–4]. Furthermore, the universal
test and treat strategy enables ART access irrespective of
CD4+ count [5], which may reduce numbers of patients
that present for care with advanced HIV disease, including
a low BMI.
Despite this strategy, we still find higher rates of mor-
bidity and mortality, driven largely by late presentation
for ART [6]. This is exacerbated by structural resource
limitations related to inadequate clinical and diagnostic
infrastructure, fewer qualified human resources, and
increased workload due to large patient volumes [4].
Currently laboratory based CD4+ count and HIV viral load
tests are the only tools used in monitoring therapeutic
outcomes in patients. The high cost and limited availability
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of personnel and infrastructure supporting use of these
tools, compounded by the need for frequent patient visits
to access laboratory results, further complicate provision of
adequate monitoring of treatment outcomes in disease
endemic settings [7]. While the world waits for more
affordable point of care diagnostics, the need for low cost,
routinely available non-invasive clinical measurements for
efficient triage of patients at high risk of adverse clinical
outcomes, remains a high priority [7, 8].
Weight loss and malnutrition are frequently described
as clinical markers for poor prognosis among HIV in-
fected patients, especially in the pre-ART era [8–13]. Se-
vere weight loss is most often due to HIV infection
itself, or an associated co-morbidity [7, 9–13]. Published
data from low-income countries demonstrate that mor-
tality was more strongly associated with weight loss
combined with co-morbid infections compared to just
CD4+ count threshold [2]. While data from South Africa
showed that patients with both prevalent and incident
tuberculosis (TB) had a two-fold greater risk of mortality
despite ART, the role of baseline BMI on clinical out-
comes had not been evaluated [2, 14].
In settings with limited diagnostic capacity, body mass
index (BMI- kg/m2), is likely to represent a number of
difficult-to-diagnose conditions such as intestinal malab-
sorption, chronic gut opportunistic infections, increased
metabolism including others [8, 9]. BMI, which provides
an estimate of healthy body weight in relation to height,
may be a useful surrogate marker of prognosis in HIV-
TB co-infection, with potential to simplify the identifica-
tion of patients at high risk of death through ease of use
[7]. A review recognized BMI as a useful predictor of
AIDS disease progression in the pre-ART era, citing its
potential use for determining survival outcomes in pa-
tients initiating ART with BMI < 18.00 [11].
Improved use of simple clinical prognostic factors
would enable early identification and triage of patients
for closer clinical observation. This would facilitate early
intervention for patients at high risk for adverse clinical
outcomes and mortality [7, 8, 10–13]. This study aimed
to assess whether there is an association between BMI
and survival among HIV infected patients initiating
ART, including a group also co-infected with TB, in
KwaZulu-Natal, South Africa.
Methods
Centre for the AIDS Programme of Research in South
Africa (CAPRISA) started a PEPFAR-funded CAPRISA
AIDS Treatment Programme (CAT) where ambulant HIV
infected, ART naïve adult patients were initiated on ART
between June 2004 and August 2013. While 1807 patients
were initiated on ART between 2008 and 2010, due to a
limited budget, we randomly selected 1000 files from this
cohort for review. The aim of conducting this retrospective
cohort study was to evaluate whether BMI predicted
survival in HIV infected patients with and without
baseline prevalent TB. Enrolment was voluntary, and
all patients were treated as per current South African
Government HIV/AIDS and Tuberculosis Treatment
Guidelines [15, 16]. Routine demographic, laboratory and
clinical data were recorded at baseline and at monthly
follow-up visits. Standard TB outcome definitions were
used as per national guidelines, and HIV viral suppression
was defined as a viral load of < 400 copies/ml [15, 16]. We
used a random number generator to randomly select
those for inclusion into this analysis after numbering pa-
tients based on chronology of enrolment [17]. Follow-up
time was calculated from ART initiation to date of death,
withdrawal from the study, loss to follow-up, transfer out
or censored at 18 months post-ART initiation, whichever
occurred first. Body mass index was calculated as per
World Health Organization (WHO) definition i.e. weight
(kg)/height (m) 2 [18]. Patients were grouped on their
baseline BMI into four categories: < 18.50 (underweight),
18.50–24.99 (normal), 25.00–29.99 (overweight), and ≥ 30.00
(obese). Primary endpoints included mortality. Secondary
endpoints included TB and HIV outcomes. This study was
approved by the Biomedical Research Ethics Committee
(BREC, reference number: E248/05) of the University of
KwaZulu-Natal.
Statistical analysis
Data were presented as means with standard deviation,
medians with interquartile range for continuous vari-
ables; and proportions for categorical data. Where ap-
propriate, Fisher–Freeman–Halton test was used to
analyse categorical data, and one-way analysis of variance
test or Kruskal–Wallis test used for analysis of continuous
data. Poisson approximations were used to calculate confi-
dence intervals (CIs) for mortality rates and mortality rate
ratios. Log-rank test was used to compare survival distri-
butions of BMI categories. Multivariate proportional haz-
ards regression was used to estimate the association
between mortality and BMI, adjusting for age, gender,
CD4+ count, TB status and WHO stage. Statistical
significance was defined as a two-sided P-value less than
0.05. Statistical analysis was performed using SAS (version
9.4; SAS Institute Inc., Cary, NC).
Results
Baseline
A total of 1000 patients were included in the analyses
(500 per treatment site) from a pool of 1807. Since height
or weight measurements were not available in 52 patients,
only 948 were included in the final analysis.
We found 15.7% (149/948) patients were underweight,
55.9% (530/948) had normal BMI, 18.7% (177/948) were
overweight and 9.7% (92/948) were obese. Female patients
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predominated in the overweight (83.1%, 147/177) and
obese (90.1%, 82/92) categories compared to male patients
(P < 0.001). Median (IQR) baseline CD4+ counts were
significantly lower in underweight patients (96 cells/mm3)
compared to normal (132 cells/mm3), overweight (150
cells/mm3) and obese (140 cells/mm3) patients (P = 0.002),
respectively. In addition, obese patients had significantly
lower baseline viral loads (4.5 log copies/ml) than
underweight (5.2 log copies/ml), normal (5.0 log copies/ml)
and overweight (4.7 log copies/ml) patients, respectively
(P < 0.001). TB prevalence at baseline among patients in
each of the BMI categories was 55.7% (83/149), 43.2%
(229/530), 32.8% (58/177) and 20.7% (19/92), respectively
(P < 0.001) (Table 1).
HIV and TB outcomes by baseline BMI
Despite statistically significant differences in mean log viral
load at baseline across the BMI categories, viral load sup-
pression rates on ART were not significantly different at 6,
12 and 18 months follow up (Table 1). TB treatment out-
comes of cure and successful TB treatment completion was
74.3%, 82.9%, 90% and 77.8% in the underweight, normal,
overweight and obese categories, respectively (P = 0.489).
Mortality
During a median follow-up of 12.8 months (interquartile
range [IQR]) 8.8 to 18 months, a total of 56 deaths
occurred over 974.2 person-years of follow-up. Under-
weight patients had higher overall mortality rates of 13.0
(95% CI: 7.8–20.3) per 100 person-years, compared to
patients that were normal 4.4 (95% CI: 2.8–6.6);
overweight 4.7 (95% CI: 2.2–9.1); and obese 4.2 (95%
CI: 1.1–10.8) per 100 person-years, respectively (P = 0.002)
(Table 2, Fig. 1). Mortality was significantly different
among the BMI categories for TB patients (Table 2).
We did not observe significant differences in mortality
rates among those with and without TB within each of
the BMI strata (Table 2).
The multivariate proportional hazards regression model
showed that underweight patients had significantly higher
risk of death compared to those with normal BMI at base-
line (aHR = 2.9; 95% CI: 1.5–5.7; P = 0.002) (Fig. 1). These
results were adjusted for baseline characteristics such as
age, gender, CD4+ count, TB status and WHO stage of
HIV. Among the variables adjusted for, only WHO
stage was a statistically significant predictor for mortality,
(aHR = 2.04; 95% CI: 1.07–3.89; P = 0.029) (Table 3).
Discussion
In high burden TB-HIV co-endemic settings, that also
have limited diagnostic capacity, an inexpensive, simple
and widely available triage tool is essential to identify pa-
tients at high risk for morbidity and early mortality.
While most studies have examined the role of BMI on
Table 1 Baseline and follow-up characteristics of patients enrolled onto ART
Variable BMI < 18.5 (N = 149) BMI (18.5–24.99) (N = 530) BMI (25–29.99) (N = 177) BMI (≥30) (N = 92) P-value
Baseline
Median (IQR), age (years)a 33 (29–39) 33.5 (29–40) 35 (28–42) 36 (30–43) 0.278
Female, %(n)b 36.9 (55) 49.6 (263) 83.1 (147) 90.1 (82) < 0.001
WHO stage 1–3,% (n)c 69.8 (104) 84.9 (450) 84.8 (150) 93.4 (85) < 0.001
WHO stage 4, % (n)c 30.2 (45) 15.1 (80) 15.3 (27) 6.6 (6)
CD4+, Median (IQR)d (cells /mm3) 96 (35–187) 132 (66–196) 150 (75–224) 140 (81–214) 0.002
Mean (SD) viral load (log copies/ml)e 5.2 (0.9) 5.0 (0.8) 4.7 (0.9) 4.5 (1.0) < 0.001
Tuberculosis at baseline 55.7 (83) 43.2 (229) 32.8 (58) 20.7 (19) < 0.001
Follow-up
CD4+ increase > 50: baseline
to 6 months, %(n) (N = 741)
78.3 (83) 80.4 (328) 74.0 (111) 70.1 (54) 0.141
CD4+ increase > 50: baseline
to 12 months, %(n) (N = 512)
85.0 (68) 85.7 (252) 83.2 (79) 83.7 (36) 0.935
CD4+ increase > 50: baseline
to 18 months, %(n) (N = 237)
85.7 (24) 91.4 (127) 91.7 (44) 86.4 (19) 0.631
Undetectable viral load at
6 months, % (n) (N = 810)
90.7 (107) 93.7 (419) 93.8 (152) 92.7 (77) 0.679
Undetectable viral load at
12 months, % (n) (N = 524)
91.5 (75) 95.0 (283) 96.0 (96) 90.9 (40) 0.401
Undetectable viral load at
18 months, % (n) (N = 242)
82.1 (23) 93.0 (132) 93.9 (46) 87.0 (20) 0.195
SD: Standard deviation IQR: Interquartile range
a2 Missing age b1 Missing WHO stage cMissing gender d112 Missing CD4+ count e92 Missing viral load
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survival in HIV mono-infected patients, we assessed the
association of BMI and survival in HIV infected patients,
some of whom were co-infected with TB. Our data
shows that baseline BMI is a strong and independent
predictor of mortality in HIV infected patients, irre-
spective of TB status. We highlight that patients who
presented with baseline BMI < 18.50 experienced 3-fold
higher mortality rates than those in higher BMI categor-
ies, regardless of tuberculosis status. It is also important
to note that mortality rates were similar in all three
BMI categories above 18.50, irrespective of tubercu-
losis co-infection.
HIV infection profoundly affects nutritional status be-
cause it is associated with poor appetite, impaired nutrient
absorption, increased basal metabolic rate and opportunis-
tic infections [2, 8]. Studies in industrialized countries
have shown a correlation between poor nutritional status
prior to ART initiation and clinical progression [9], whilst
studies from Africa have demonstrated a correlation be-
tween low baseline BMI and subsequent higher mortality.
Furthermore, data from a Malawian cohort of tuberculosis
patients, among whom 80% were HIV co-infected, found
that a baseline BMI < 17.00 independently predicted
mortality within the first 4 weeks of starting tuberculosis
treatment. Baseline BMI in this cohort, is similar to pub-
lished data from African patients, but lower than BMI in
studies from European countries [7, 9].
In the study by Forouzanfar et al. the proportion of
females was 4-fold higher compared to males in the
> 30.00 BMI group [19]. In 2008, the average BMI in
South Africa was 26.9 kg/m2 among males (vs. a world
average of 23.80 kg/m2), and 29.50 kg/m2 among females
(vs. a world average of 24.1 kg/m2) [20]. Interestingly, a
recent meta-analysis from 1990 to 2015 found that unsafe
Table 2 Mortality rates for different BMI classification
BMI < 18.5 BMI 18.5–24.99 BMI 25–29.99 BMI≥ 30 P-value**
Deaths/
person-years
Mortality
rate (95% CI)
Deaths/
person-years
Mortality
rate (95% CI)
Deaths/
person-years
Mortality
rate (95% CI)
Deaths/
person-years
Mortality
rate (95% CI)
All 19/146.2 13.0 (7.8–20.3) 24/545.0 4.4 (2.8–6.6) 9/188.2 4.7 (2.2–9.1) 4/94.8 4.2 (1.1–10.8) 0.002
TB 11/80.8 13.6 (6.8–24.5) 7/240.6 2.9 (1.2–6.0) 5/60.7 8.2 (2.7–19.2) 1/19.2 5.2 (0.1–29.1) 0.007
No TB 8/65.4 12.2 (5.3–24.1) 17/304.4 5.6 (3.2–8.9) 4/127.5 3.1 (0.9–8.0) 3/75.7 4.0 (0.8–11.6) 0.076
P-value* 0.818 0.147 0.150 0.851
BMI Body Mass Index
*P-value comparing TB and no TB group within each BMI stratum
**P-value comparing BMI strata across each TB category
Fig. 1 Kaplan-Meier estimates of cumulative probability of death, by BMI group
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sex and high BMI was ranked first and second leading risk
factors for early death and disability in South Africa. In a
maturing HIV epidemic, the likely impact of high BMI on
non-communicable diseases related morbidity and mortal-
ity is very concerning given the large numbers of patients
receiving chronic ART.
We could not demonstrate an association between
CD4+ counts and BMI, as the range of CD4+ counts in
our study was small due to the ART eligibility criteria.
We do however show that CD4+ count was not an
independent predictor of mortality.
In a study conducted in four sub-Saharan countries in-
vestigating timing of ART in TB-HIV co-infected patients
with CD4+ > 220 cells/mm3, overall mortality rates were
low, despite a baseline BMI of < 18.50 in approximately
40% of patients [12]. A study evaluating correlation
between BMI and CD4+ count gains found that baseline
BMI predicted change in CD4+ count after week 96.
Relative to men with normal BMI, overweight and obese
men had higher CD4+ count increases. It is clear from
these studies that low baseline BMI together with low
CD4 counts predict mortality, while high BMI is
associated with larger CD4+ counts increases, the latter
only due to the impact of ART [12].
Criteria used to clinically stage HIV disease, and diag-
nose AIDS defining illnesses, are internationally accepted
but are often difficult to apply in resource-poor environ-
ments, as they require sophisticated and expensive investi-
gations to make definitive diagnoses [21]. Furthermore,
AIDS care is usually delivered by nurses, who are exposed
to limited clinical and diagnostic training reducing their
ability to appropriately identify and up-refer patients at
high risk for poor outcomes. Thus, there is clearly a need
for less sophisticated prognostic clinical indicators suitable
for task-shifted activities conducted by frontline health
care workers in resource limited settings.
We acknowledge several limitations of the study. Data
used in this analysis was routinely collected program-
matic data, which was flawed by missing data variables
on height and weight, reducing our analysable sample.
Autopsies are not routinely performed for HIV infected
patients that demise. Autopsy data would have improved
our understanding of the causes of mortality by the dif-
ferent BMI categories. While we see similar mortality
rates among obese patients compared to those with a
BMI between 18.50–29.90, these findings need further
evaluation given the very small sample size in the obese cat-
egory. Furthermore, we followed-up patients for 18 months
only. Longer follow-up may have provided valuable infor-
mation on BMI changes following chronic ART, and a
further understanding of BMI category on risk of non-
communicable disease in clade C HIV infected patients.
Conclusions
BMI is associated with mortality in HIV infected patients
initiating ART and is regarded as an affordable, low-
technology, prognostic indicator; independent of age, sex,
CD4+ count, or HIV type. Further prospective studies are
indicated to evaluate whether BMI could be used to inform
intervention decisions, including decisions of when to refer
patients for diagnostic work-up or admission.
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